v3.26.1
Segment Reporting - Summary of Reconciliation of Revenue to Net Income (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Total revenue $ 131,948   $ 86,679   $ 249,648 $ 171,364
Less:            
Depreciation and amortization expense         6,710 7,322
Stock-based compensation expense 10,654   9,424   20,457 18,355
Litigation settlement expense 0   350   600 5,710
Gain on sale of lab products business     0   (112,966) 0
Interest income, net (1,735)   (2,364)   (3,644) (5,148)
Net income (loss) 110,636 $ 2,809 (8,568) $ (10,353) 113,445 (18,921)
Testing services revenue            
Segment Reporting [Line Items]            
Total revenue 99,927   62,033   191,325 123,954
Less:            
Cost of test services, product, and patient and digital solutions 15,918   15,406   33,015 30,519
Product revenue            
Segment Reporting [Line Items]            
Total revenue 12,791   11,833   23,137 22,643
Less:            
Cost of test services, product, and patient and digital solutions 4,342   4,981   9,176 10,567
Patient and digital solutions revenue            
Segment Reporting [Line Items]            
Total revenue 19,230   12,813   35,186 24,767
Less:            
Cost of test services, product, and patient and digital solutions 14,706   8,271   26,404 15,987
Reportable Segment            
Segment Reporting [Line Items]            
Total revenue 131,948   86,679   249,648 171,364
Less:            
Personnel cost 49,033   29,330   91,221 60,073
Professional and legal fees 5,861   12,348   13,773 22,540
Research materials and clinical trials expense 4,088   4,057   7,919 7,231
Depreciation and amortization expense 2,057   2,951   5,176 5,901
Stock-based compensation expense 10,615   9,424   20,382 18,355
Litigation settlement expense 0   350   600 5,710
Business development and portfolio optimization expense 11,078   0   14,435 0
Transformational initiative costs 0   1,871   0 1,871
Gain on sale of lab products business (112,966)   0   (112,966) 0
Other segment items 18,991   10,189   32,851 19,970
Interest income, net (1,735)   (2,364)   (3,644) (5,147)
Net income (loss) 110,636   (8,568)   113,445 (18,921)
Reportable Segment | Testing services revenue            
Segment Reporting [Line Items]            
Total revenue 99,927   62,033   191,325 123,954
Less:            
Cost of test services, product, and patient and digital solutions 15,516   14,731   32,037 29,134
Reportable Segment | Product revenue            
Segment Reporting [Line Items]            
Total revenue 12,791   11,833   23,137 22,643
Less:            
Cost of test services, product, and patient and digital solutions 4,327   4,431   8,560 9,374
Reportable Segment | Patient and digital solutions revenue            
Segment Reporting [Line Items]            
Total revenue 19,230   12,813   35,186 24,767
Less:            
Cost of test services, product, and patient and digital solutions $ 14,447   $ 7,929   $ 25,859 $ 15,273